Master Alliance Provisions Guide (MAPGuide)

MedinCell – MPP, Malaria Vector Control (mdc-STM/ivermectin formulation) License Agreement

  • Term & termination | Term of agreement

13. DURATION AND TERMINATION

13.1 This Agreement will take effect on the Effective Date and, unless terminated earlier as provided herein, shall continue in force until the date on which the last Licensed Patent associated with the Licensed Technology has expired, lapsed or has been invalidated.

Schedule 3. Development Agreement Term Sheet

2. Term: The Sub-licence Agreement will be in force from the date of its signature until the date on which the last Licensed Patent associated with the Licensed Technology has expired, lapsed or has been invalidated. MPP shall have the right to either terminate the Development Agreement, or to require the Development Partner to novate the Development Agreement to MedinCell (i.e. by entering into a Novation Agreement with MPP and MedinCell), in the event that the MPP-MedinCell Agreement is terminated.

Schedule 4. Commercialisation Agreement Term Sheet

2. Term: The Commercialisation Agreement will be in force from the date of its signature until the date on which the last Licensed Patent associated with the Licensed Technology has expired, lapsed or has been invalidated. MPP shall have the right to either terminate the Commercialisation Agreement, or to require the Commercialisation Partner to novate the Commercialisation Agreement to MedinCell (i.e. by entering into a Novation Agreement with MPP and MedinCell), in the event that the MPP-MedinCell Agreement is terminated. Upon termination, Commercialisation Partner will immediately provide MPP with details of the stocks of Final Products held at the point of termination.